5-Fluorouracil, doxorubicin, and cisplatin as treatment for adrenal cortical carcinoma.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 2044046.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Fourteen patients with progressive metastatic adrenal cortical carcinoma were treated with a combination of 5-fluorouracil (5-FU), doxorubicin, and cisplatin (FAP). All had a large tumor burden. Six patients had a hormone-producing tumor; mitotane treatment was given to five of them during chemotherapy for its possible antihormonal effects. Treatment could be evaluated in 13 patients. The overall response rate was 23% (95% confidence interval [CI], 5% to 54%). A complete remission, which lasted for 42 months, was achieved in one patient. Partial remissions, which lasted for 6 and 11 months, were achieved in two patients. Cardiotoxicity appeared in three patients, myelotoxicity in four, and nephrotoxicity in one. This confirms that this regimen is an active combination for the treatment of metastatic adrenal cortical carcinoma.
Medical subject headings
- Adrenal Cortex Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma
- Cisplatin
- Doxorubicin
- Fluorouracil